Compare Amphastar Pharmaceuticals Inc (AMPH) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Health Care Select Sector SPDR Fund — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Health Care Select Sector SPDR Fund trades at $167.94. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XLV | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | — |
52-Week High | $30.81 | $168.44 |
52-Week Low | $16.87 | $131.16 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
XLV trades at $165.68, up 0.75% with a bullish technical signal from moving averages. The healthcare ETF shows strong defensive positioning amid market volatility, with recent articles highlighting its cost efficiency at 0.08% expense ratio and $41.7 billion AUM. Technical indicators show support at $164 and resistance at $167, with RSI levels in neutral territory suggesting balanced momentum.
The outlook remains positive given healthcare's defensive characteristics and recent sector inflows. Key risks include regulatory pressures and competitive ETF offerings, but XLV's diversification across 60 healthcare stocks provides stability. Analyst comparisons favor XLV for lower costs and steady performance versus specialized biotech ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
